Kiniksa Pharmaceuticals, Ltd. Earnings Recaps
Q3 2026
Oct 28, 2026
Kiniksa’s shares rose 22.2% after earnings, as the company raised full-year revenue guidance to $1.045–$1.050 billion and said ARCALYST is on track to exceed $1 billion in 2026. Q3 ARCALYST revenue was $286 million, with penetration among patients with multiple recurrences reaching 23%.
Key takeaways
- ARCALYST revenue reached $286 million in Q3; management raised full-year revenue guidance to $1.045–$1.050 billion.
- ARCALYST penetration of the annual 14,000-patient multiple-recurrence population rose to 23% by quarter-end. The company is also targeting an additional 26,000 patients annually experiencing a first recurrence.
- Management cited growing physician consideration of ARCALYST earlier in the disease course; about 50% of surveyed physicians support its use after NSAIDs and colchicine and before corticosteroids.
- KPL-387’s pivotal Phase III trial continues to enroll and dose patients, with data expected in the second half of 2027. Kiniksa is targeting a potential launch in 2028–2029.
- KPL-1161 is on track to enter a Phase I trial by year-end.
Q2 2026
Jul 30, 2026
Kiniksa shares surged 27.4% following significant upside in ARCALYST commercial performance and raised full-year revenue guidance, signaling strong execution and expanding market penetration.
Key takeaways
- Q2 net revenue reached $243.6 million, up over $29 million sequentially and $85 million versus Q2 2025, marking the largest quarterly increase since launch.
- Full-year 2026 revenue guidance was raised from $945 million to a range of $980 million to $995 million.
- ARCALYST’s prescriber base expanded to over 5,000, with approximately 450 new prescribers added in Q2 and 29% now prescribing for multiple patients.
- Penetration into the multiple recurrence patient population increased to ~21% from ~18% at the end of 2025.
- The company advanced KPL-387 into Phase III trials, targeting a commercial launch in 2028–2029.
Q3 2025
Oct 28, 2025
Kiniksa Pharmaceuticals reported strong third-quarter results, with ARCALYST revenue reaching $180.9 million, reflecting significant growth and a revised full-year sales guidance increase.
Key takeaways
- ARCALYST revenue grew by approximately $69 million year-over-year and $24 million sequentially.
- Full-year net sales guidance raised to $670 million - $675 million, up from previous guidance of $625 million - $640 million.
- KPL-387 received FDA Orphan Drug Designation for recurrent pericarditis, enhancing future growth potential.
- New patient enrollments surged, with a total prescriber count exceeding 3,825, indicating strong market penetration and adoption.
- The average duration of ARCALYST therapy increased to approximately 32 months, reflecting patient satisfaction and treatment effectiveness.